This article describes legislative and commercial drivers for propellant change and potential propellants, as well as the Respitab® technology platform, which provides a novel approach to formulation and manufacturing of lower global warning potential (GWP) pMDIs. Studies are presented and manufacturing and considerations for its use are discussed. There is a clear need for alternatives […]
There is a need to adopt more environmentally friendly pMDI propellants, not only to reduce carbon footprint, but also to mitigate supply issues that may result from the decline in the use of existing propellants. HFA-152a and HFO-1234ze(E) are two potential candidates. It is critical that drug developers and manufacturers prepare their facilities for the […]
As the inhalation community explores propellants with lower global warming potential that could be used in pressurized metered dose inhalers (pMDIs), we hear the term “Kigali Amendment to the Montreal Protocol.” But how does that differ from the Paris Agreement? A useful explanation is shown in this table, reprinted with kind permission of the Montreal […]
In the case of formulations under development for indications such as pain management, migraine, seizure and biologics such as vaccines, which require a delivery system with precision control over spray plume geometry and deposition to the nasal mucosa for systemic uptake, pharmaceutical manufacturers have turned their attention to unit-dose, aseptic intranasal drug products. This type […]
The second in a series of articles on the history of DPI capsules. Part 1 appeared in the December, 2008 issue of Inhalation.